• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract Risk of serious infection in patients with moderate to severe psoriasis is associated with the type of biologic treatment

byKathleen Lau
August 13, 2021
in StudyGraphics
0
Share on FacebookShare on Twitter

RELATED REPORTS

2 Minute Medicine Rewind June 27, 2022

Ustekinumab and adalimumab comparable in safety and efficacy for treatment of Crohn’s disease

Subcutaneous risankizumab maintenance therapy superior to placebo for moderate-severe Crohn’s disease

Tags: adaliumumabapremilastbiologicbiologicscalcipotrioldermatologyetanerceptgastrointestinal infectionGuselkumabIL-17 inhibitorIL-23 inhibitorinfectioninfectious diseasesInfliximabinterleukin 12/23 inhibitorpsoriasisskinTNF inhibitortumor necrosis factor inhibitorustekinumabvitamin d derivative
Previous Post

Aerobic exercise after 2 PM did not affect sleep amongst people with depression

Next Post

2 Minute Medicine Rewind August 16, 2021

RelatedReports

Implementation of pneumococcal vaccine programs linked to decreased antibiotic prescription
Chronic Disease

2 Minute Medicine Rewind June 27, 2022

June 27, 2022
Thalidomide may be effective in refractory pediatric Crohn’s disease
Chronic Disease

Ustekinumab and adalimumab comparable in safety and efficacy for treatment of Crohn’s disease

June 21, 2022
Thalidomide may be effective in refractory pediatric Crohn’s disease
Chronic Disease

Subcutaneous risankizumab maintenance therapy superior to placebo for moderate-severe Crohn’s disease

June 8, 2022
Biosimilar to infliximab shows equivalent safety and efficacy for treating Crohn’s disease
Chronic Disease

Risankizumab induction therapy is effective for moderate-to-severe Crohn’s disease

June 7, 2022
Next Post
Low free sugar diet reduces hepatic steatosis in nonalcoholic fatty liver disease in adolescent males

2 Minute Medicine Rewind August 16, 2021

Oral ondansetron administration in children seeking emergency department care for acute gastroenteritis

Psychological impact of COVID-19 on health care workers in Singapore

Women may be more likely to experience sleep issues during the COVID-19 pandemic

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • ACKR1 variant increases risk of azathioprine-related hematopoietic toxicity
  • #VisualAbstract: Molnupiravir improves outcomes in non-hospitalized COVID-19 patients
  • Intraperitoneal chemotherapy improves advanced ovarian cancer survival [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.